Last reviewed · How we verify
Typhoid Vi polysaccharide
Typhoid Vi polysaccharide is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of typhoid fever in individuals traveling to or living in areas where typhoid fever is common. Also known as: Typhim Vi.
Typhoid Vi polysaccharide vaccine induces an immune response against Salmonella Typhi.
Typhoid Vi polysaccharide is a vaccine component used to prevent infections caused by Salmonella Typhi, a bacterium that can lead to conditions such as Typhoid and Paratyphoid Fever. It is a vaccine component, as indicated by its listing in ChEMBL, and has been studied in various clinical trials, including those for Typhoid Fever and Salmonella Infections, as listed on ClinicalTrials.gov.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
Sanofi Pasteur, a Sanofi Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Typhoid Vi polysaccharide |
|---|---|
| Also known as | Typhim Vi |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is achieved by presenting the Vi polysaccharide antigen to the immune system, which then mounts a specific response against the bacteria. The vaccine does not contain live or attenuated bacteria, making it safe for use in individuals with weakened immune systems.
Approved indications
- Prevention of typhoid fever in individuals traveling to or living in areas where typhoid fever is common
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Vellore Typhoid Vaccine Impact Trial (PHASE4)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women (NA)
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Inflammatory Challenge and Fear (PHASE1)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever (PHASE1, PHASE2)
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Typhoid Vi polysaccharide CI brief — competitive landscape report
- Typhoid Vi polysaccharide updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Typhoid Vi polysaccharide
What is Typhoid Vi polysaccharide?
How does Typhoid Vi polysaccharide work?
What is Typhoid Vi polysaccharide used for?
Who makes Typhoid Vi polysaccharide?
Is Typhoid Vi polysaccharide also known as anything else?
What development phase is Typhoid Vi polysaccharide in?
What are the side effects of Typhoid Vi polysaccharide?
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of typhoid fever in individuals traveling to or living in areas where typhoid fever is common
- Also known as: Typhim Vi
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing